Showing results (161-170 of 227) with videos related to
Sort By:
Pageof 23
American Journal of Hematology|October 23, 2024
Toxicities and outcome after CD19-directed chimeric antigen receptor T-cell therapy for secondary neurolymphomatosisLeon D Kaulen, Philipp Karschnia, Sofia Doubrovinskaia, et al.Science (New York, N.Y.)|April 15, 2014
Neuronal activity promotes oligodendrogenesis and adaptive myelination in the mammalian brainErin M Gibson, David Purger, Christopher W Mount, et al.The Lancet. Haematology|October 13, 2022
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trialReuben Benjamin, Nitin Jain, Marcela V Maus, et al.Blood|January 27, 2026
Ruxolitinib for Ciltacabtagene Autoleucel-Associated Refractory DiarrheaViktoria Blumenberg, Filippo Birocchi, Angela Shih, et al.Cell|April 28, 2015
Neuronal Activity Promotes Glioma Growth through Neuroligin-3 SecretionHumsa S Venkatesh, Tessa B Johung, Viola Caretti, et al.Journal for Immunotherapy of Cancer|September 9, 2020
Cell-based artificial APC resistant to lentiviral transduction for efficient generation of CAR-T cells from various cell sourcesAndrea Schmidts, Leah C Marsh, Ambike A Srivastava, et al.Nature|April 14, 2022
CAR T cell killing requires the IFNγR pathway in solid but not liquid tumoursRebecca C Larson, Michael C Kann, Stefanie R Bailey, et al.The New England Journal of Medicine|May 3, 2019
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple MyelomaNoopur Raje, Jesus Berdeja, Yi Lin, et al.Nature Medicine|August 17, 2023
Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trialYi Lin, Noopur S Raje, Jesús G Berdeja, et al.Science Translational Medicine|January 7, 2021
Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomideMax Jan, Irene Scarfò, Rebecca C Larson, et al.Pageof 23